Table 2.
Distribution of patients based on tumor regression grade and pathological and radiological features
| Pathological complete and major pathological response N = 9 |
Non-major pathological response N = 41 |
p valuea |
|||
|---|---|---|---|---|---|
| TRG 0 N = 7 |
TRG 1 N = 2 |
TRG 2 N = 16 |
TRG 3 N = 25 |
||
| Histological grade: well differentiated moderately differentiated poorly differentiated |
1 (14.3%) 1 (14.3%) 5 (71.4%) |
0 (0.0%) 1 (50.0%) 1 (50.0%) |
0 (0.0%) 9 (56.3%) 7 (43.7%) |
2 (8.0%) 10 (40.0%) 13 (52.0%) |
0.376 |
| PDL1 (CPS) <1 1≥ to <5 ≥5 to <10 ≥10 unknown |
0 (0.0%) 2 (28.6%) 2 (28.6%) 2 (28.6%) 1 (14.3%) |
0 (0.0%) 2 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) |
0 (0.0%) 1 (6.3%) 4 (25.0%) 9 (56.3%) 2 (12.5%) |
4 (16.0%) 9 (36.0%) 4 (16.0%) 6 (24.0%) 2 (8.0%) |
0.439 0.943 0.751 0.341 |
| PDL1 (TPS) low (<70) high (≥70) unknown |
6 (85.7%) 0 (0.0%) 1 (14.3%) |
2 (100.0%) 0 (0.0%) 0 (0.0%) |
13 (81.2%) 1 (6.3%) 2 (12.5%) |
23 (92.0%) 0 (0.0%) 2 (8.0%) |
>0.999 |
| MMR status preserved deficient unknown |
4 (57.1%) 2 (28.6%) 1 (14.3%) |
2 (100.0%) 0 (0.0%) 0 (0.0%) |
12 (75.0%) 3 (18.8%) 1 (6.3%) |
23 (92.0%) 3 (12.0%) 1 (4.0%) |
0.601 |
| HER2 status positive negative unknown |
0 (0.0%) 5 (71.4%) 2 (28.6%) |
1 (50.0%) 1 (50.0%) 0 (0.0%) |
0 (0.0%) 15 (93.8%) 1 (6.3%) |
2 (8.0%) 22 (88.0%) 1 (4.0%) |
0.398 |
| Change in SUVmax >35% <35% |
5 (71.4%) 2 (28.6%) |
1 (50.0%) 1 (50.0%) |
13 (81.2%) 3 (18.8%) |
14 (56.0%) 11 (44.0%) |
>0.999 |
a
Comparing MPR vs. non-MPR status.